Brooks Laboratories gets nod to manufacture Doripenem Monohydrate injection

08 Dec 2011 Evaluate

Brooks Laboratories has received an approval for manufacture of Doripenem Monohydrate injection from Directorate General of Health Service. The company is all set to manufacture this drug within this fiscal year.

Doripenem is a broad spectrum anti-bacterial agent of carbapenem family. Growing bacterial resistance is major cause of concern for researchers as it contributors to increase in mortality, morbidity and treatment cost. Doripenem is an ultra broad spectrum anti bacterial agent of carbepenem family used to treat in complicated intra-abdominal infections and complicated urinary tract infections, including complicated and uncomplicated pylenephritis and cases with concurrent bacteremia.

Brooks Laboratories is into pharmaceutical contract research and manufacturing services. It is having wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc.

Brooks Laboratories Share Price

165.50 3.20 (1.97%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.